Aptinyx Inc [NASDAQ: APTX]
Clinical-stage biopharmaceutical company Aptinyx Inc., reported today of its positive results from the second phase of its novel NVDA receptor module, NYX-783 clinical trial.
The study involved 153 patients suffering from post-traumatic-stress disorder (PTSD). In this study, NYX-783 showed statistically and clinically significant efficacy results of this treatment. Following these results, Aptinyx expects to kick-start a serious study in 2021. PTSD is one of the most difficult psychiatric conditions to treat due to multiple debilitating symptoms.
Murray Stein, the Vice-Chair for Clinical Research in Psychiatry at the University of California San Diego says that it is encouraging to get such positive results and considering the short duration that NYX-783 takes to cure this disorder.
Uxin Ltd [NASDAQ: UXIN]
Uxin Limited, an international online Chinese company dealing with used cars recently announced that it has entered into two definitive agreements with two investors that will see the company raise US$25,000,000.
In these agreements, Uxin plans to issue an aggregate of 84,692,839 Class A ordinary shares through private placements that will occur in October 2020. Additionally, Uxin also entered into a letter agreement with affiliates of TPG, 58.com and Warburg Pincus to alter the conversion of price of the convertible notes in an aggregate total of about US$230 million.
Based on this letter in two years after the agreement, if the Company issues or sells any equity securities less than the conversion price, the strategic investors will have a right to convert all or a part of their convertible notes at a price that is equal to New Issue Price.
Iterum Therapeutics Plc [NASDAQ: ITRM]
Iterum Therapeutics plc announced today that it will present its data at the Infectious Disease Society of America IDWeek that will take place virtually as from October 21, 2020.
The data presentations will include results for SURE-2, that will show the effects in complicated urinary tract infections (cUTI) and oral abstract presentation that are results from SURE-1 in uncomplicated urinary tract infections..
This data shows that oral sulopenem was statistically stronger than oral ciprofloxacin to treat patients with uncomplicated urinary tract infections. Iterum Therapeutics is a clinical-stage pharmaceutical institution that is focussed on developing oral and IV antibiotics for the treatment and management of infections caused by drug resistant pathogens in both hospital and home settings.
